Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016
Published Jul 20, 2016
103 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016, provides in depth analysis on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
- The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indicat

  
Source:
Document ID
GMDHC0398TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Overview91
Therapeutics Development104
  Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Stage of Development101
  Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Therapy Area111
  Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Indication122
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Pipeline Products Glance142
  Late Stage Products141
  Early Stage Products151
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Companies165
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Products under Development by Universities/Institutes212
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Therapeutics Assessment237
  Assessment by Monotherapy/Combination Products231
  Assessment by Mechanism of Action242
  Assessment by Route of Administration262
  Assessment by Molecule Type282
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Companies Involved in Therapeutics Development3020
  Amgen Inc.301
  ArQule, Inc.311
  Astellas Pharma Inc.321
  AstraZeneca Plc331
  AVEO Pharmaceuticals, Inc.341
  Blueprint Medicines Corporation351
  Bristol-Myers Squibb Company361
  Daiichi Sankyo Company, Limited371
  Eddingpharm381
  Eisai Co., Ltd.392
  Eli Lilly and Company411
  Genosco421
  H3 Biomedicine Inc.431
  Ionis Pharmaceuticals, Inc.441
  Johnson &Johnson451
  NGM Biopharmaceuticals, Inc.461
  Novartis AG471
  Principia Biopharma Inc.481
  Vichem Chemie Research Ltd.491
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Drug Profiles5038
  ARQ-087 Drug Profile502
  ASP-5878 Drug Profile521
  AZ-709 Drug Profile531
  BLU-554 Drug Profile542
  BLU-9931 Drug Profile561
  BMS-986036 Drug Profile571
  EDP-317 Drug Profile581
  erdafitinib Drug Profile592
  FGF-401 Drug Profile611
  H-3B6527 Drug Profile621
  infigratinib Drug Profile632
  IONIS-463588 Drug Profile651
  lenvatinib mesylate Drug Profile6611
  LQN-725 Drug Profile771
  LY-2874455 Drug Profile781
  Monoclonal Antibody to Antagonize FGFR4 for Cancer Drug Profile791
  NGM-282 Drug Profile802
  PRN-1371 Drug Profile821
  Recombinant Protein to Agonize FGFR for Type 2 Diabetes Drug Profile831
  Recombinant Proteins to Agonize FGFR for Metabolic Disorders Drug Profile841
  Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma Drug Profile851
  Small Molecules to Antagonize Pan FGFR for Oncology Drug Profile861
  U3-1784 Drug Profile871
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Dormant Projects881
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Discontinued Products891
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Featured News &Press Releases9012
  Jul 04, 2016: Eisai Launches In-House Developed Novel Anticancer Agent Lenvima In Mexico901
  Jun 30, 2016: ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer901
  Jun 23, 2016: ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer911
  Jun 06, 2016: Principia Biopharma Announces Presentation of Initial Clinical Data on PRN1371 at 2016 American Society of Clinical Oncology Annual Meeting911
  May 31, 2016: City Of Hope researchers present data on BGJ398 at the American Society of Clinical Oncology s Annual Meeting921
  May 24, 2016: Eisai To Present on Lenvima at 52nd Annual Meeting of the American Society of Clinical Oncology921
  May 16, 2016: U.S. FDA Approves additional indication for Eisai anti cancer agent LENVIMA in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma931
  Apr 20, 2016: Eisai Announces Non-Clinical Research Findings At Aacr 107Th Annual Meeting Regarding Combination Of Anticancer Agent Lenvatinib With Everolimus941
  Apr 12, 2016: Highly Anticipated New Treatment Option Now Available for Canadians with Select Type of Thyroid Cancer951
  Mar 09, 2016: Lenvima (lenvatinib) Now Available in Israel as Important New Treatment for People with Advanced Thyroid Cancer961
  Feb 25, 2016: Eisai Slams the New Cancer Drug Fund that Further Delays Patient Access to New Cancer Drug971
  Jan 18, 2016: U.S. FDA Accepts for Priority Review sNDA for Eisai S Anticancer Agent Lenvatinib Seeking Approval for Renal Cell Carcinoma981
  Jan 12, 2016: Eisai Submits New Application In Europe For In-House Developed Anticancer Agent Lenvatinib Seeking Approval For Indication Covering Renal Cell Carcinoma982
  Dec 16, 2015: Lenvima (lenvatinib) Now Reimbursed for Advanced Thyroid Cancer in Sweden1001
  Dec 15, 2015: ArQule Announces Orphan Drug Designation in Cholangiocarcinoma and Clinical Update for ARQ 0871002
Appendix1022
  Methodology1021
  Coverage1021
  Secondary Research1021
  Primary Research1021
  Expert Panel Validation1021
  Contact Us1021
  Disclaimer1031

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Fibroblast-Growth-Factor-Receptor-4-CD334-or-FGFR4-or-EC-2-7-10-1-Pipeline-Review-H2-2016-2088-16280>
  
APA:
Global Markets Direct - Market Research. (2016). Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Fibroblast-Growth-Factor-Receptor-4-CD334-or-FGFR4-or-EC-2-7-10-1-Pipeline-Review-H2-2016-2088-16280>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.